妊娠期慢性高血压的个体化管理探索
本文为叙述性综述,回顾近年数据以指导妊娠期慢性高血压的当前诊疗与未来研究。慢性高血压增加母儿并发症风险,家庭血压监测可行,降压治疗可减半进展为重度高血压等的风险,但未观察到先兆子痫或严重母体并发症减少。作者认为证据基础正在增长并与国际指南一致,解决未决研究问题将有助于个体化管理。
要点
- 慢性高血压增加母儿并发症风险,家庭血压监测设备已普及,患者可参与自我管理。
- 降压治疗可使进展为重度高血压、血小板减少和肝酶升高的风险减半,但未观察到先兆子痫或严重母体并发症减少。
- 降压治疗不减少也不增加胎儿或新生儿死亡或发病率,与开始治疗的孕周无关。
核心结论
- 指导妊娠期慢性高血压孕妇诊疗的证据基础正在增长并与国际指南一致,解决未决研究问题将有助于个体化管理。
研究设计与样本
- 本研究为已发表文献的叙述性综述。
主要发现
- 与血压正常女性相比,慢性高血压女性母儿并发症风险增加。
- 降压治疗可使进展为重度高血压、血小板减少和肝酶升高的风险减半,但未观察到先兆子痫或严重母体并发症减少;后者的证据缺乏可能因事件数少。
- 降压治疗不减少也不增加胎儿或新生儿死亡或发病率,与开始降压治疗的孕周无关。
- 降压药物无致畸性,但慢性高血压本身可能与畸形增加相关。
- 基于观察性文献,在38 0/7至39 6/7周之间定时分娩可能改善结局;确证性试验证据尚待公布。
关键数值与推荐
- 慢性高血压在妊娠中的发生率为1%至2%。
- 重叠型先兆子痫的诊断标准仍存在问题,因多数指南继续将血压控制恶化纳入定义。
- 血管生成标志物在疑似重叠型先兆子痫诊断中的附加价值尚未确立,超出常规临床数据和实验室结果所提供的信息。
- 阿司匹林可降低先兆子痫风险,但在慢性高血压女性中的特异性有效性受到质疑;钙在该人群中预防先兆子痫的独立作用尚不明确。
- 目前临床使用的血压治疗目标与家庭血压目标相同,尽管高血压女性家庭血压值往往不一致地偏低。
临床怎么用
- 慢性高血压女性若希望参与自身照护,可通过家庭血压监测实现;准确的设备现已 readily available。
- 目前诊所血压治疗目标与家庭血压目标相同。
- 基于观察性文献,在38 0/7至39 6/7周之间定时分娩可能改善结局;确证性试验证据尚待公布。
- 多数降压药(包括血管紧张素转换酶抑制剂)可用于母乳喂养,便于产后照护。
局限性
- 重叠型先兆子痫的诊断标准仍存在问题,因多数指南继续将血压控制恶化纳入定义。
- 血管生成标志物在疑似重叠型先兆子痫诊断中的附加价值尚未确立。
- 阿司匹林在慢性高血压女性中预防先兆子痫的特异性有效性受到质疑;钙的独立作用尚不明确。
- 未观察到先兆子痫或严重母体并发症减少,证据缺乏可能因事件数少。
- 尚不清楚是否存在最佳降压药物或最佳联合用药方式;定时分娩的结局改善基于观察性文献,确证性试验证据尚待公布。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic hypertension complicates 1% to 2% of pregnancies, and it is increasingly common. Women with chronic hypertension are an easily recognized group who are in touch with a wide variety of healthcare providers before, during, and after pregnancy, mandating that chronic hypertension in pregnancy be within the scope of many practitioners. We reviewed recent data on management to inform current care and future research. This study is a narrative review of published literature. Compared with normotensive women, women with chronic hypertension are at an increased risk of maternal and perinatal complications. Women with chronic hypertension who wish to be involved in their care can do by measuring blood pressure at home. Accurate devices for home blood pressure monitoring are now readily available. The diagnostic criteria for superimposed preeclampsia remain problematic because most guidelines continue to include deteriorating blood pressure control in the definition. It has not been established how angiogenic markers may aid in confirmation of the diagnosis of superimposed preeclampsia when suspected, over and above information provided by routinely available clinical data and laboratory results. Although chronic hypertension is a strong risk factor for preeclampsia, and aspirin decreases preeclampsia risk, the effectiveness specifically among women with chronic hypertension has been questioned. It is unclear whether calcium has an independent effect in preeclampsia prevention in such women. Treating hypertension with antihypertensive therapy halves the risk of progression to severe hypertension, thrombocytopenia, and elevated liver enzymes, but a reduction in preeclampsia or serious maternal complications has not been observed; however, the lack of evidence for the latter is possibly owing to few events. In addition, treating chronic hypertension neither reduces nor increases fetal or newborn death or morbidity, regardless of the gestational age at which the antihypertensive treatment is started. Antihypertensive agents are not teratogenic, but there may be an increase in malformations associated with chronic hypertension itself. At present, blood pressure treatment targets used in clinics are the same as those used at home, although blood pressure values tend to be inconsistently lower at home among women with hypertension. Although starting all women on the same antihypertensive medication is usually effective in reducing blood pressure, it remains unclear whether there is an optimal agent for such an approach or how best to use combinations of antihypertensive medications. An alternative approach is to individualize care, using maternal characteristics and blood pressure features beyond blood pressure level (eg, variability) that are of prognostic value. Outcomes may be improved by timed birth between 38 0/7 and 39 6/7 weeks' gestation based on observational literature; of note, confirmatory trial evidence is pending. Postnatal care is facilitated by the acceptability of most antihypertensives (including angiotensin-converting enzymes inhibitors) for use in breastfeeding. The evidence base to guide the care of pregnant women with chronic hypertension is growing and aligning with international guidelines. Addressing outstanding research questions would inform personalized care of chronic hypertension in pregnancy.
引用
- Magee LA, Khalil A, Kametas N, et al. Toward personalized management of chronic hypertension in pregnancy. Am J Obstet Gynecol. 2020. PMID: 32687817. doi:10.1016/j.ajog.2020.07.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。